What is SeqMatic?
Headquartered in Fremont, California, SeqMatic operates as a specialized provider of next-generation sequencing (NGS) and multi-omics solutions. The company distinguishes itself through a science-first methodology, offering a comprehensive suite of services that spans DNA, RNA, and single-cell sequencing, alongside advanced histopathology and bioinformatics analysis. By maintaining a CLIA-licensed and CAP-accredited laboratory, SeqMatic ensures that its output meets the rigorous standards required by research institutions and corporate partners worldwide.
The company's market position is defined by its commitment to rapid turnaround times and personalized service, which are critical in the competitive landscape of genomic research. By integrating sophisticated sequencing technology with robust data interpretation, SeqMatic serves as an essential partner for organizations navigating the complexities of modern biological data, effectively bridging the gap between raw sequencing output and actionable scientific insights.
How much funding has SeqMatic raised?
SeqMatic has raised a total of $300K across 2 funding rounds:
Debt
$150K
Debt
$150K
Debt (2020): $150K with participation from PPP
Debt (2021): $150K led by PPP
Key Investors in SeqMatic
PPP
Public-Private Partnership
What's next for SeqMatic?
With the successful acquisition of its latest capital, SeqMatic is well-positioned to enhance its technological infrastructure and expand its service portfolio. The strategic focus will likely center on increasing throughput capacity within its Fremont facility and potentially broadening its bioinformatics capabilities to address the growing complexity of multi-omics data sets. As the industry shifts toward more personalized medicine and precision diagnostics, the company's ability to maintain high-quality, scalable operations will be paramount.
Future growth initiatives are expected to prioritize the optimization of laboratory workflows and the expansion of its client base across international research markets. By maintaining its focus on technical excellence and regulatory compliance, SeqMatic is poised to capitalize on the increasing reliance of the pharmaceutical and academic sectors on outsourced, high-fidelity genomic sequencing services.
